Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Atom Bioscience Says Gout Treatment Meets Phase II Efficacy/Safety Endpoints

publication date: Mar 1, 2023

Jiangsu Atom Bioscience reported positive results from its China Phase IIa clinical trial of the company’s lead candidate, ABP-671, a treatment for gout. ABP-671 is a small molecule candidate that inhibits the urate transporter 1 (URAT1) protein. By reducing the reabsorption of uric acid in the kidneys, ABP-671 increases the excretion of uric acid. Atom says ABP-671 is more potent and significantly less toxic than existing drugs. The company plans to start China Phase III trials in 2023. Atom Bioscience develops small molecule therapeutics that treat inflammatory and metabolic diseases. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital